This week there were 23 Top Picks and 7 ETF in a wide range of industries: Technology, ETF, Financials, Healthcare, Industrials, Consumer and Energy.
A upgrade today helped lift the stock. A satisfed customer base will keep this stock going. He disagrees with Wall St. that Apple is overvalued now. Consider Apple's enormous overseas' earnings during a weak US dollar--a big tailwind. Third, the Apple Watch owns that space. Fourth, under Biden there won't be a worry of a…
(A Top Pick Oct 08/19, Up 60%) They have really done well expanding their card-based usage throughout the world. We are in a world that is moving from cash to cashless. No one has found a way to disrupt them. Their network gets used more and more and cash flow goes back to shareholders.
They increase the yield on utilities with covered calls. It is not a bad place to be. You are always subject to the underlying securities' risks. It is probably a good choice right now.
(A Top Pick Dec 04/18, Up 2%) Safety play. A place to park cash. Never touches a GIC, because they're not liquid.
US companies that are constantly increasing their dividends over time. It has a lot of very familiar names in it. He thinks it will continue to perform well. It is more into the value sector.
(A Top Pick May 07/20, Up 12%) Strongly outperformed the broad market starting late February. It was a pandemic trade. From late March to early June, it gave it all back. We've seen a baseline, and now it's starting to outperform again. August and September are dangerous times for the market, so this is a…
If you are getting exposure to US energy, he expects US pipelines to be at capacity so playing it through the MLP is a good strategy. The dividend cut was in response to the pressure on energy price. He owns for the yield and not cap gains.
We've seen the bounce from March 23, but they haven't performed well since then. There's lack of visibility on the future. Until we get past Covid, it's not his favourite sector. It has structural headwinds against it. People are out of work, and we haven't had the wave of bankruptcies yet. Better places to look.
(A Top Pick May 07/20, Up 8%) Healthcare sector is a bit exhausted right now, and seeing relative weakness. He's walked back from it a bit. Coming up to an election, healthcare can become a political football.
It is a more international bank, especially in South America which should start to do better. They offer a good yield. A very good place to be. Balance sheet and liquidity is strong. It is yielding over 5%. (Analysts’ price target is $68.19)
A spin-off of Brookfield Asset Management. For every 170 shares of BAM-T one owned, they received one share of TSU-T. They underwrite smaller BTB insurance. They can sell-off re-insurance for a recurring fee stream in the US – a process called “fronting”. On paper it looks like they operate at a loss, but it will…
Tough year for the banks. Q4 will be released in a few weeks, and you never know what you're going to get. Brighter days are ahead, and the market's already figured that out. BMO is not his favourite. Prefers National, TD, Royal. You'll do fine with the Canadian banks. Some concerns around fintech. Low interest…
The premier property casualty company in North America. They are not subject to low interest rates because they reset their prices every year. 10 times earnings and double digit growth for the last decade. It is on sale today. Minimal impact from CoVid19. (Analysts’ price target is $124.25)
Owns 21,000 single-family units in the US sunbelt; this sector has seen a major tailwind during Covid. Covid has seen strong demand for spacious, suburban housing. Renting such a single-family home is cheaper (by sq. ft.) than a multi-family unit. TCN has enjoyed cash flow grow. Compared to its U.S. peers, TCN is very cheap.…
(A Top Pick Dec 05/18, Up 45%) It's a Blackstone-sponsored company that bought a bunch of single-family homes and rent them out. Blackstone IPO'd this and sold it in tranches over time. Now, the stock has legs and doesn't need the parent's support. They rent to tenants and are adding ancillary businesses, like pet services…
Admires the management, but he doesn't like commercial office space now, but ARE's tenants are American biotech and life science companies, which carry the costs of. A lot of value here.
He does not own this one, despite the earnings metrics looking solid and there is no net debt. They missed on a recent quarterly earning, but not a bid deal. They are trading at 7 times cash flow and 7 times EBITDA. He would like to see the ROE improve a bit. Price momentum has…
He won't offer a buy-sell-hold verdict. BHC has done a good reorganization. There's talk of spinning out their eye division. Has a 6.5% EBITDA-to-debt ratio, so there's still some debt. They're still restructuring, so there will be little growth.
This stock should skate through a change in administration or even another Trump term. Americans are quite happy with private healthcare solutions. 180M Americans have some sort of private health. 75% are happy with this so it would probably not be disrupted in a large way. He prefers Anthem but there is no problem with…
(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.
(A Top Pick Sep 29/20, Down 5.9%)Stockchase Research Editor: Michael O'Reilly We are recommending to cover MRK as it has violated our stop-loss. We are going to look for better opportunities.
You want to buy it when it's on sale. A bit rich here. The diagnostics is an area of growth, but we'll have to wait and see. Hold, if you have a good entry point. Good quality company longer term. Not a buyer at this point.
He sold it about two weeks ago when they put out the vaccine news. He was looking to trim or sell anyway. They are going through the spin-off of their generic business (UpJohn). He does not think the vaccine will be a long term driver on their financials. They had a miss in their oncology…
(A Top Pick Nov 18/19, Down 38%) Buses are in the crosshairs of the pandemic. Governments are greening their infrastructure, and NFI will benefit. A leader in electrification of buses and infrastructure. Future is bright, just on pause. You could do well 3-5 years from now.
They lead in wireless antennae for cell phones, satellites and sell globally. The pandemic has impacted sales. They had to pause a new plant in Vietnam. The 5G roll-out is back on track. They had to guide down and that pressured the stock. Also have a lot of debt. Overall, though, they will be fine…
Price target: 2,000 Yen An unknown niche Japanese company. Boasts zero debt and pays a near 4% dividend yield. Trades at a very cheap valuation. Creates fine shareholder value.
It is an interesting business. It is specialty pharmacies. They do medication for long term care facilities. They have an interesting pouch technology. They had quite a significant debt load and made a big dent in it when they sold their surgical business. They are trying to pick up new contracts. He has owned it…
Organic growth plus acquisition-driven growth. Rolling up a fragmented industry very capably with their decades of experience. Pivoting more to organic growth, which will attract more investors. Great company, great buy. Yield is 0.81%. (Analysts’ price target is $52.20)
One of the beneficiaries of the terrible energy market. It is well managed and capitalized. The largest integrated energy companies in Canada. Focused on expense management. It is planning on increasing cashflow in the next couple years. Yield is around 4%. (Analysts’ price target is $25.41)